Rapid and Accurate Diagnosis of Paediatric TB (RaPaed-AIDA-TB) (RaPaed)

Rapid and Accurate Diagnosis of Paediatric (RaPaed) TB - An AIDA (Assessment of Innovative Diagnostics and Algorithms for Early and Sensitive Detection of Acute TB) Platform Study

This study will serve as a platform to evaluate new diagnostics in children suspected to have TB, establish diagnostic performance (sensitivity and specificity) and calculate positive and negative predictive values in a real-life cohort.

Finally, this study will comprise the results of several tests in its database. This will allow simulation of diagnostic algorithms, that may be composed of screening (i.e. rule-out) tests together with confirmatory tests to maximize sensitivity and specificity.

Study Overview

• Status: Completed
• Conditions: Tuberculosis; Diagnoses Disease
• Intervention / Treatment: Diagnostic test: Sample collection

Detailed Description

Tuberculosis (TB) is a major cause of child morbidity and mortality in the world. There are an estimated one million new paediatric cases and at least 239.000 deaths per year. As childhood mortality on TB treatment is low at 1%, this highlights the fact that a large proportion of cases are never diagnosed and thereby never receive appropriate treatment.

The inability to correctly and timely diagnose paediatric TB is the main obstacle to controlling disease and preventing adverse outcomes, specifically among infants and young children, children with malnutrition, HIV infection, and drug-resistant TB. Paediatric samples, which are difficult to obtain, have small volumes and low bacterial burden, leading to the low sensitivity of currently applied diagnostic tests for TB, which are geared towards adults.

The World Health Organization has clearly stated that new and improved diagnostics for children are a top priority.

With RaPaed TB, the Sponsor (LMU) designed a project that is ideally suited to evaluate a range of novel diagnostics and sampling strategies in a population of symptomatic children with presumptive TB with a high likelihood of mycobacteriological confirmation of disease. The key aspects of this project are a multi-site collaboration of five geographically distinctive sites in highly TB endemic settings allowing a large sample size, and a high proportion of bacteriologically confirmed cases and making study findings generalizable.

Internationally recognized experts in child TB clinical research are included in the study; FIND's panel of diagnostic tests and expertise in diagnostics development and evaluation as well in the WHO submission and review process of the gathered data; LMU with its track record of delivering high-quality studies in the TB field; two large industry partners dedicated to the development of robust point-of-care assays; and finally, early involvement of National TB Programmes in the studies which will not only add to local capacity development, but also enable rapid local approval and uptake.

974 paediatric patients were enrolled into the RaPaed study in the four African and one Indian sites, with an average confirmation rate of 24% (study target: 25%).

Ten new diagnostic techniques suitable for children are being assessed in this study. These include a new stool protocol and Nasopharyngeal Aspirate for Xpert® MTB/RIF Ultra, TAM-TB from the University of Munich/Beckman Coulter Inc., a host biomarker panel by the University of Stellenbosch, host RNA tests, host protein biomarker tests (i.e. FIND and SomaLogic's host-response serum markers), and two novel urinary LAM tests (i.e. UriTB direct, FUJIFILM-urinary-LAM), and Cepheid's Fingerprick test.

It is realistic to think that this study will lead to WHO endorsement or recommendation of at least two or more new assays or sampling strategies; with FIND leading the WHO submission process which could therefore impact childhood TB policies globally.

In this third period of the RaPaed-TB study, all relevant study documents have been maintained such as the protocol, the Manual of Procedures, SOPs and Worksheets for collecting the data.

Ethics approval for the study conduct and all updates have been obtained centrally and in all study sites by the time of submission of this report.

The database has been maintained and updated, fulfilling its function for study data collection and analysis, as well as enabling study oversight and quality control.

• Study Type: Observational
• Enrollment (Actual): 974

Contacts and Locations

Study Locations

• India
  • Tamil Nadu
    • Vellore, Tamil Nadu, India, 632004
      • Christian Medical College
• Malawi
  • Blantyre, Malawi
    • University of Malawi College of Medicine
• Mozambique
  • Maputo, Mozambique, PO.BOX 264
    • Centro de Investigação e Treino em Saúde da Polana Caniço
• South Africa
  • Cape
    • Cape Town, Cape, South Africa
      • University of Cape Town Lung Institute (UCTLI)
• Tanzania
  • Mbeya, Tanzania, P.O. Box 2410
    • NIMR - Mbeya Medical Research Programme

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 10 years (Child)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients 14 years old or younger with a suspicion of active TB are eligible for recruitment into the study, if they meet the specified inclusion criteria, and none of the exclusion criteria.

Description

Inclusion Criteria:

1. Consent and Assent (if applicable): signed written consent/assent, or witnessed oral consent/assent in the case of illiteracy, before undertaking any study-specific activity. The age threshold for child assent requirement will be laid down in each the Investigator Site File based on the local Ethics Committee requirement.

   Of the following, either criterion 2), OR criterion 3), or both, have to be met:

2. Confirmation of TB disease: microbiological confirmation of active TB disease by positive smear AND/OR culture AND/OR PCR (e.g. GeneXpert®); e.g. in a non-study health facility AND/OR

3. Signs and Symptoms: suspicion of active TB disease (one or more criteria):

   1. Chest X-ray suggestive of TB: cavity AND/OR hilar/mediastinal lymph node enlarged AND/OR military pattern
   2. Weight loss or failure to thrive within the previous 3 months that, in the investigator's opinion, is not solely due to inadequate feeding; or to another non-TB cause.
   3. Any cough combined with loss of weight
   4. Cough alone: duration of > 14 days
   5. Repeated episodes of fever within 14 days not responding to course of antibiotics AND positive TST or IGRA, (for malaria endemic areas: AND after malaria has been excluded by at least a negative rapid test)*

   6. Signs & symptoms of extrapulmonary TB:

      • Enlarged lymph nodes for > 2 weeks, not painful to palpation;
      • Gibbus (especially of recent onset)
      • Non-painful enlarged joint
      • Pleural effusion
      • Pericardial effusion
   7. CSF examination findings in line with TB meningitis with at least elevated protein and low glucose (in relation to serum glucose); OR signs and symptoms in line with TB meningitis/CNS TB if lumbar puncture is contraindicated, in the view of the investigator:

At least one of the following two:

• palsy of oculomotoric nerves of recent onset
• focal neurological symptoms indicating elevated intracranial pressure OR CNS lesions, of recent onset

AND/OR at least two of the following less specific signs of TB meningitis/CNS TB (for malaria endemic areas: AND a negative malaria rapid diagnostic test*):

• Lethargy
• Convulsion
• Meningism (neck stiffness)
• Headache (*the requirement of negative MRDT may be dropped in agreement with the sponsor during study conduct.)

Exclusion Criteria:

1. Critical condition (if study procedures seems like an undue risk to patient's life), such as hypovolemic shock or clinically relevant anaemia (tachypnoea, tachycardia)
2. Body weight is less than 2 kg
3. Children of 15 years of age or older
4. Are currently receiving anti-TB drug(s): ideally, eligible patients should not have received any anti-TB treatment. In exceptions, up to three daily doses given since treatment start before first study blood draw are acceptable for study inclusion

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Paediatric diagnostic group	Diagnostic test: Sample collection; Specimen collection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sensitivity and Specificit of new test candidates; against a clinica/microbiological reference standard case definition	The case definition has been defined by an NIH-convened expert panel, published in 2012 and updated in 2015 (S. Graham et al.; CID). This definition describes the diagnostic certainty for a child to suffer from TB. Possible classifications: Confirmed active tuberculosis; Unconfirmed tuberculosis; Unlikely tuberculosis This case definition will be made based on the following: Confirmed active tuberculosis: bacteriological confirmation obtained (TB lab; positive culture AND/OR WHO endorsed PCR).; Unconfirmed tuberculosis: bacteriological confirmation NOT obtained AND at least two of the following: Symptoms suggestive of TB X-ray suggestive of TB Close exposure to TB Positive response to TB treatment • Unlikely tuberculosis: defined as bacteriological confirmation NOT obtained AND criteria for "unconfirmed tuberculosis" NOT met	6 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ability of new tests to measure response to TB treatment, by measuring the change in experimental test readout over time while receiving TB treatment	Rate of change of new test readout (e.g. antigen detection rates), in children who receive TB treatment	6 months
Proportion of children with confirmed TB, and with other diseases, who have acute and chronic lung impairment using spirometry	Spirometry parameters: forced vital capacity (FVC) in l; forced expiratory volume in 1 second (FEV 1)	12 months

Collaborators and Investigators

• Sponsor: Michael Hoelscher
• Collaborators: Karolinska Institutet; University of Stellenbosch; University of Cape Town Lung Institute; Foundation for Innovative New Diagnostics, Switzerland; Kamuzu University of Health Sciences; Instituto Nacional de Saúde, Mozambique; University of Melbourne; National Institute for Medical Research, Tanzania; Christian Medical College, Vellore, India; Research Center Borstel; Beckman Coulter, Inc.; Cepheid; Otsuka Novel Products GmbH
• Investigators: Principal Investigator: Michael Hoelscher, Professor, University Hospital, LMU Munich; Study Director: Norbert Heinrich, MD, University Hospital, LMU Munich

Study record dates

Study Major Dates

• Study Start (Actual): January 21, 2019
• Primary Completion (Actual): December 31, 2022
• Study Completion (Actual): December 31, 2022

Study Registration Dates

• First Submitted: June 22, 2018
• First Submitted That Met QC Criteria: November 5, 2018
• First Posted (Actual): November 7, 2018

Study Record Updates

• Last Update Posted (Actual): May 1, 2023
• Last Update Submitted That Met QC Criteria: April 28, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: Tuberculosis; Diagnostics; Paediatrics
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Actinomycetales Infections; Mycobacterium Infections; Disease; Tuberculosis
• Other Study ID Numbers: LMU-IMPH-AIDA-02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No